HK1085511A1 - Complement inhibitors from ticks - Google Patents

Complement inhibitors from ticks

Info

Publication number
HK1085511A1
HK1085511A1 HK06105580.9A HK06105580A HK1085511A1 HK 1085511 A1 HK1085511 A1 HK 1085511A1 HK 06105580 A HK06105580 A HK 06105580A HK 1085511 A1 HK1085511 A1 HK 1085511A1
Authority
HK
Hong Kong
Prior art keywords
complement inhibitors
ticks
complement
relates
inhibitors
Prior art date
Application number
HK06105580.9A
Other languages
English (en)
Inventor
Miles Andrew Nunn
Original Assignee
Varleigh Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312619A external-priority patent/GB0312619D0/en
Priority claimed from GB0327386A external-priority patent/GB0327386D0/en
Application filed by Varleigh Ltd filed Critical Varleigh Ltd
Publication of HK1085511A1 publication Critical patent/HK1085511A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • G01N2333/43556Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects from ticks
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/42Poisoning, e.g. from bites or stings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
HK06105580.9A 2003-06-02 2006-05-15 Complement inhibitors from ticks HK1085511A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0312619A GB0312619D0 (en) 2003-06-02 2003-06-02 Complement inhibitors
GB0327386A GB0327386D0 (en) 2003-11-25 2003-11-25 Complement inhibitors
PCT/GB2004/002341 WO2004106369A2 (en) 2003-06-02 2004-06-02 Complement inhibitors from ticks

Publications (1)

Publication Number Publication Date
HK1085511A1 true HK1085511A1 (en) 2006-08-25

Family

ID=33492257

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06105580.9A HK1085511A1 (en) 2003-06-02 2006-05-15 Complement inhibitors from ticks

Country Status (13)

Country Link
US (5) US7884188B2 (ja)
EP (1) EP1629098B1 (ja)
JP (1) JP4772667B2 (ja)
AT (1) ATE427356T1 (ja)
AU (1) AU2004242759B2 (ja)
BR (1) BRPI0410876B8 (ja)
CA (1) CA2526083C (ja)
DE (1) DE602004020334D1 (ja)
ES (1) ES2324993T3 (ja)
HK (1) HK1085511A1 (ja)
MX (1) MXPA05012880A (ja)
NZ (1) NZ544163A (ja)
WO (1) WO2004106369A2 (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629098B1 (en) * 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US8088579B2 (en) 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
EP1885398B1 (en) 2005-05-26 2015-07-08 The Regents of the University of Colorado, a body corporate Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
NZ568384A (en) 2005-12-12 2011-09-30 Ac Immune Sa Therapeutic vaccine comprising Abeta peptide
CA2662716C (en) * 2006-09-08 2017-11-21 Varleigh Limited Method of treating respiratory disorders
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PL2148691T3 (pl) * 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
WO2008140653A2 (en) 2007-03-14 2008-11-20 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
CN101928709B (zh) * 2009-06-24 2012-05-23 中国农业科学院上海兽医研究所 一种亚洲璃眼蜱的组胺结合蛋白HaHBP的基因序列和重组表达与应用
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2785612C (en) * 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 for use in the treatment of viral infections of the respiratory tract
CA2792622A1 (en) 2010-03-11 2011-09-15 University Of Louisville Research Foundation, Inc. Methods of predicting and decreasing the risk of pregnancy loss
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
US8961981B2 (en) * 2011-06-20 2015-02-24 Saint Louis University Targeting the neuromuscular junction for treatment
MX363606B (es) 2011-06-22 2019-03-28 Apellis Pharmaceuticals Inc Uso de inhibidores del complemento en trastornos crónicos.
AU2013222836B2 (en) 2012-02-20 2017-07-20 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement C5
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
US20200325449A1 (en) 2016-06-02 2020-10-15 The Cleveland Clinic Foundation Complement inhibition for improving cell viability
KR102534895B1 (ko) 2016-06-14 2023-05-24 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
EP4275696A1 (en) 2017-04-21 2023-11-15 Volution Immuno Pharmaceuticals SA Coversin for the treatment of autoimmune blistering diseases
AU2018383751A1 (en) 2017-12-13 2020-06-25 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
EP3849588A1 (en) 2018-09-10 2021-07-21 Volution Immuno Pharmaceuticals SA Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
EP4034237A1 (en) 2019-09-27 2022-08-03 Volution Immuno Pharmaceuticals SA Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3734093A (en) * 1992-02-27 1993-09-13 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US7884066B2 (en) * 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP1629098B1 (en) * 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks

Also Published As

Publication number Publication date
ATE427356T1 (de) 2009-04-15
DE602004020334D1 (de) 2009-05-14
US8993264B2 (en) 2015-03-31
US7884188B2 (en) 2011-02-08
JP2007536894A (ja) 2007-12-20
CA2526083A1 (en) 2004-12-09
EP1629098B1 (en) 2009-04-01
US20070141573A1 (en) 2007-06-21
BRPI0410876A (pt) 2006-07-04
BRPI0410876B8 (pt) 2023-01-24
US20160096870A1 (en) 2016-04-07
EP1629098A2 (en) 2006-03-01
ES2324993T3 (es) 2009-08-21
JP4772667B2 (ja) 2011-09-14
CA2526083C (en) 2017-01-17
US20220363726A1 (en) 2022-11-17
WO2004106369A2 (en) 2004-12-09
AU2004242759A1 (en) 2004-12-09
US9834585B2 (en) 2017-12-05
AU2004242759B2 (en) 2009-11-26
MXPA05012880A (es) 2006-02-22
WO2004106369A3 (en) 2005-02-17
NZ544163A (en) 2009-06-26
BRPI0410876B1 (pt) 2020-11-03
US20110263482A1 (en) 2011-10-27
US20180127472A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
HK1085511A1 (en) Complement inhibitors from ticks
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
WO2003105840A3 (en) SPHINGOSINE KINASE INHIBITORS
GB0223040D0 (en) Therapeutic compounds
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
NO20034056D0 (no) Proliferative sykdommer
MXPA05012812A (es) Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
DK1420801T3 (da) Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
IS7669A (is) Aðferðir til að meðhöndla eða fyrirbyggja með 2,4-pyrímidíndíamín efnasamböndum sjálfsónæmissjúkdóma
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
EP1553951A4 (en) COMPOSITIONS CONTAINING A JNK INHIBITOR FOR TREATING, PREVENTING, MANAGING AND / OR MODIFYING PAIN, AND METHODS OF USE THEREOF
DK1581235T3 (da) Anvendelse af spongosin (2-methoxyadenosin) til behandling af smerte i særdeleshed hyperalgesi
HK1082923A1 (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency
EP1667976A4 (en) Isoquinolinone POTASSIUM CHANNEL INHIBITORS
DE60329326D1 (de) Tace inhibitoren
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
WO2004060878A3 (en) Inhibitors of phosphatases
HUP0401633A2 (hu) Irbesartan alkalmazása pulmonális magas vérnyomás megelőzésére vagy kezelésére alkalmas gyógyszerkészítmény előállítására
WO2003072053A3 (en) Compounds for treatment of copper overload